Browse CDKN1C

Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF02234 Cyclin-dependent kinase inhibitor
Function

Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001701 in utero embryonic development
GO:0001822 kidney development
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0001933 negative regulation of protein phosphorylation
GO:0006469 negative regulation of protein kinase activity
GO:0007050 cell cycle arrest
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007346 regulation of mitotic cell cycle
GO:0007423 sensory organ development
GO:0007568 aging
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0021700 developmental maturation
GO:0030099 myeloid cell differentiation
GO:0030325 adrenal gland development
GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway
GO:0033673 negative regulation of kinase activity
GO:0035264 multicellular organism growth
GO:0035270 endocrine system development
GO:0042326 negative regulation of phosphorylation
GO:0042551 neuron maturation
GO:0043010 camera-type eye development
GO:0045786 negative regulation of cell cycle
GO:0048469 cell maturation
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048732 gland development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0051348 negative regulation of transferase activity
GO:0055123 digestive system development
GO:0060065 uterus development
GO:0060669 embryonic placenta morphogenesis
GO:0061458 reproductive system development
GO:0071514 genetic imprinting
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0072001 renal system development
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903846 positive regulation of cellular response to transforming growth factor beta stimulus
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0004861 cyclin-dependent protein serine/threonine kinase inhibitor activity
GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity
GO:0019207 kinase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
GO:0030291 protein serine/threonine kinase inhibitor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04110 Cell cycle
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-69231: Cyclin D associated events in G1
R-HSA-69236: G1 Phase
R-HSA-453279: Mitotic G1-G1/S phases
Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CDKN1C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CDKN1C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CDKN1C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.0760.0247
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3160.439
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9010.486
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7880.146
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9560.553
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5770.778
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1540.68
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3410.726
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7480.502
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6880.592
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0550.545
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0280.882
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDKN1C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDKN1C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDKN1C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDKN1C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CDKN1C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CDKN1C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCDKN1C
Namecyclin-dependent kinase inhibitor 1C (p57, Kip2)
Aliases BWCR; Beckwith-Wiedemann syndrome; p57Kip2; cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase i ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CDKN1C collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.